Iconic Brand Was The First Product Of Its Kind To Receive
U.S. Food And Drug Administration Approval In 2002 For Aesthetic
Use And Is Honoring This Milestone By Celebrating Its Loyal
Patients And Providers
IRVINE,
Calif., April 13, 2022 /PRNewswire/ -- Allergan
Aesthetics, an AbbVie company (NYSE: ABBV), announces the
celebration of a milestone moment for
BOTOX® Cosmetic (onabotulinumtoxinA). April 15, 2022, will mark 20 years since the U.S.
Food and Drug Administration (FDA) first approved the product to
temporarily improve the look of moderate to severe glabellar lines,
located between your eyebrows.1 It was the first product
of its kind and has since received two additional aesthetic
indications – in 2013 and 2017 – making BOTOX®
Cosmetic the first and only neurotoxin that is FDA-approved for
adults to temporarily improve the look of moderate to severe lines
in three areas; frown lines, crow's feet and forehead
lines.2-5
"It has been remarkable to see how BOTOX® Cosmetic
has evolved in 20 years, one scientific study at a time that
showcases the clinical significance of this treatment," said Dr.
Jean Carruthers, MD, FRCSC, FRC
(Poth). "BOTOX® Cosmetic has not only changed the
trajectory of my career but also the way the medical aesthetics
community practices and teaches. By any account, two decades is a
long time, however in medicine it is just the beginning, and I look
forward to the next big milestone for BOTOX®
Cosmetic."
"This celebration is about reflecting on the people who helped
make BOTOX® Cosmetic a household name," said
Carrie Strom, Senior Vice President,
AbbVie, and President, Global Allergan Aesthetics. "We
celebrate our customers, our colleagues and all the patients who
have been a part of our success. We remain dedicated to
BOTOX® Cosmetic, the first product of its kind on the
market. We are passionate about continuing to drive this market
forward and our experienced team is working closely with healthcare
providers to ensure we are delivering meaningful innovations that
the market needs with our commitment to ongoing research."
BOTOX® Cosmetic is bringing its celebration to the
public with its first-ever Art Installation which will be on a
cross-country tour. Visitors can immerse themselves in a highly
visual, interactive experience that takes them on a celebratory
journey of self-affirmation. The installation will be unveiled in
New York City on Friday, April 22nd at 9 am ET and will be open to the public until
Saturday, April 23rd
before traveling to Chicago from
Friday, May 6th to
Sunday, May 8th and
finally, Los Angeles from
Friday, May 20th to
Sunday, May 22nd. Starting
on May 30th for eight
weeks, a version of the installation will be featured at Resorts
World in Las Vegas. Anyone who
visits the Art Installation will be eligible to receive an
exclusive BOTOX® Cosmetic offer powered by
Allē®, Allergan Aesthetics' loyalty platform, while
supplies last. Terms and conditions apply.
Additionally, to spotlight the people behind the product, the
celebration will feature a documentary style video highlighting
real patients and providers of BOTOX® Cosmetic – helping
to paint a colorful picture of how and why people continue to see
BOTOX® Cosmetic as a treatment for someone like them.
Starting April 15th, watch
the video at www.botoxcosmetic20thcelebration.com and
@BotoxCosmetic on social.
To take the celebration nationwide, exclusive BOTOX®
Cosmetic offerings will be available to both new and loyal
BOTOX® Cosmetic patients starting in April. These
offerings include a chance to win a trip for two to see Resort
World's new Allē Lounge on 66, in addition to tickets to a concert.
Register for the chance to win between April
15th and April
29th by visiting
www.botoxcosmetic20thcelebration.com and following the steps
on the site. This is a limited time offer. Terms and conditions
apply.
Allergan Aesthetics, the makers of
BOTOX® Cosmetic, is the exclusive aesthetics
partner of Resorts World Las Vegas and will have exclusive branding
rights to the property's 66th floor lounge, now known as
Allē Lounge on 66, and Resorts World Theatre's meet-and-greet
space, Allē Backstage. This is the first official
partnership with an entitlement of this kind at Resorts World Las
Vegas since its June 2021 grand
opening, and Allergan Aesthetics' first-ever branding of a specific
area at a major resort and live entertainment venue. The
partnership is the first of its kind across the aesthetics
industry.
Visit https://alle.com/ to join Allē, Allergan Aesthetics'
loyalty program, which is required to attend the
BOTOX® Cosmetic Art Installation and to participate
in the limited-time sweepstakes and gift card offering. Terms and
conditions apply. Follow us on Instagram @botoxcosmetic and
@alle, in addition to using the hashtag
#20yearsofbotoxcosmetic.
BOTOX® COSMETIC IMPORTANT SAFETY
INFORMATION
BOTOX® Cosmetic may cause serious side
effects that can be life threatening. Get medical help right away
if you have any of these problems any time (hours to weeks) after
injection of BOTOX® Cosmetic:
- Problems swallowing, speaking, or breathing, due to weakening
of associated muscles, can be severe and result in loss of life.
You are at the highest risk if these problems are pre-existing
before injection. Swallowing problems may last for several
months.
- Spread of toxin effects. The effect of botulinum toxin may
affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same as,
or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin
effect when BOTOX® Cosmetic has been used at the
recommended dose to treat frown lines, crow's feet lines, and/or
forehead lines.
BOTOX® Cosmetic may cause loss of strength or
general muscle weakness, vision problems, or dizziness within hours
to weeks of taking BOTOX® Cosmetic. If this
happens, do not drive a car, operate machinery, or do other
dangerous activities.
Serious and/or immediate allergic reactions have been
reported. They include: itching, rash, red itchy welts,
wheezing, asthma symptoms, or dizziness or feeling faint. Get
medical help right away if you are wheezing or have asthma
symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you:
are allergic to any of the ingredients in
BOTOX® Cosmetic (see Medication Guide for
ingredients); had an allergic reaction to any other botulinum toxin
product such as Myobloc® (rimabotulinumtoxinB),
Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin
infection at the planned injection site.
Tell your doctor about all your muscle or nerve
conditions, such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased
risk of serious side effects including difficulty swallowing and
difficulty breathing from typical doses of
BOTOX® Cosmetic.
Tell your doctor about all your medical conditions,
including: plans to have surgery; had surgery on your face;
have trouble raising your eyebrows; drooping eyelids; any other
abnormal facial change; are pregnant or plan to become pregnant (it
is not known if BOTOX® Cosmetic can harm your
unborn baby); are breast-feeding or plan to (it is not known if
BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
supplements. Using BOTOX® Cosmetic with certain
other medicines may cause serious side effects. Do not start any
new medicines until you have told your doctor that you have
received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such as Myobloc®, Dysport®, or
Xeomin® in the past (tell your doctor exactly which
product you received); have recently received an antibiotic by
injection; take muscle relaxants; take an allergy or cold medicine;
take a sleep medicine; take aspirin-like products or blood
thinners.
Other side effects of BOTOX® Cosmetic
include: dry mouth; discomfort or pain at the injection site;
tiredness; headache; neck pain; and eye problems: double vision,
blurred vision, decreased eyesight, drooping eyelids and eyebrows,
swelling of your eyelids and dry eyes.
APPROVED USES
BOTOX® Cosmetic is a
prescription medicine that is injected into muscles and used to
temporarily improve the look of moderate to severe forehead lines,
crow's feet lines, and frown lines between the eyebrows in
adults.
For more information refer to the Medication Guide or talk with
your doctor.
To report a side effect, please call Allergan at
1-800-678-1605.
Please see BOTOX® Cosmetic full Product
Information including Boxed Warning and Medication Guide.
About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company, develops, manufactures, and
markets a portfolio of leading aesthetics brands and products.
Their aesthetics portfolio includes facial injectables, body
contouring, plastics, skin care, and more. Their goal is to
consistently provide customers worldwide with innovation,
education, exceptional service, and a commitment to excellence, all
with a personal touch.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
References:
- Data on File. AbbVie. FDA Product Approval Information,
2019.
- BOTOX® Cosmetic Prescribing Information,
July 2020.
- Dysport® Prescribing Information, 2020.
- Xeomin® Prescribing Information, 2020.
- Jeuveau® Prescribing Information, 2020.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-celebrates-20-years-since-first-us-fda-approval-301524587.html
SOURCE AbbVie